1 |
Dewit, L. (1987) Combined treatment of radiation and cisdiamminedichloro-platinum (II): a review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys. 13, 403-426
ScienceOn
|
2 |
Furuse, K., Kubota, K., Kawahara, M., Kodama, N., Ogawara, M., et al. (1995) Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 13, 869-875
|
3 |
Kelland, L. R. (1993) New platinum antitumor complexes. Crit. Rev. Oncol./Hematol. 15, 191-219
DOI
ScienceOn
|
4 |
Kim, D. K., Kim, H. T., Tai, J. H., Cho, Y. B., Kim, T. S., et al. (1995a) Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato-(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane-platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother. Pharmacol. 37, 1-6
|
5 |
Kohno, N., Kitahara, S., Tamura, E., and Tanabe, T. (2002) Concurrent chemoradio-therapy with low-dose cisplatin plus 5-Fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology 63, 226-231
DOI
ScienceOn
|
6 |
Leichman, L., McDonald, B., Dindogru, F. A., Samson, M., and Vaitkevicius, V. K. (1984) An active drug in the treatment of disseminated gastric cancer. Cancer 53, 18-22
DOI
ScienceOn
|
7 |
Reed, E., Dabholkar, M., and Chabner, B. A. (1996) Platinum analogues; in Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner, B. A. and Longo, D. I. (eds.), pp. 357, Lippincott-Raven, Philadelphia
|
8 |
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., et al. (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10, 263-270
DOI
ScienceOn
|
9 |
Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol. Parmacol. 59, 657-663
|
10 |
Kim, D. K., Kim, G., Gam, J., Cho, Y. B., Kim, H. T., et al. (1994a) Synthesis and antitumor activity of a series of 2-substituted-4,5-bis(aminomethyl)-1,3-dioxolaneplatinum(II) complexes. J. Med. Chem. 37, 1471-1485
DOI
ScienceOn
|
11 |
Kim, N. K., Kim, T. Y., Shin, S. G., Park, Y. L., Lee, J. A., et al. (2001) A phase I study of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane]plaTINUM(II) in patients with advanced malignancies. Cancer 91, 1549-1556
DOI
ScienceOn
|
12 |
Lee, Y. S., Kang, K. S., Shin, D. J., Cho, J. J., Kim, H. O., et al. (1992) Subacute toxicity of cis-malonato(4R,5R)-4,5-bis-(aminomethyl)-1,3-dioxolane-platinum(II) (SKI 2053R) in beagle dogs. Korean J. Toxicol. 8, 235-m254
|
13 |
Hong, W. S., Kim, H. T., Kim, K. H., and Kim, D. K. (1995) In vitro antitumor activity of a new platinum complex, cismalonato (4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res. 15, 51-54
|
14 |
Kim, N. K., Im, S. A., Kim. D. W., Lee, M. H., Jung, C. W., et al. (1999) Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer 86, 1109-1115
DOI
ScienceOn
|
15 |
Joiner, M. C., Lambin, P., and Marples, B. (1999) Adaptive response and induced resistance. C. R. Acad. Sci. III. 322, 167-175
ScienceOn
|
16 |
Kokubo, M., Nagata, Y., Nishimura, Y., Kimura, H., Shoji, K., et al. (2001) Concurrent chemoradiotherapy for oropharyngeal carcinoma. Am. J. Clin. Oncol. 24, 71-m96
DOI
ScienceOn
|
17 |
Tannock, I. F. (1994) New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer 10, 29-m51
DOI
ScienceOn
|
18 |
Fram, R. J. (1992) Cisplatin and platinum analogues: recent advances. Curr. Opin. Oncol. 4, 1073
ScienceOn
|
19 |
Potish, R. A., Twiggs, L. B., and Adcock, L. L. (1986) Effect of cisplatinum on tolerance to radiation therapy in advanced cervical cancer. Am. J. Clin. Oncol. 9, 387-m391
ScienceOn
|
20 |
Rosenberg, B. (1999) Platinum complexes for the treatment of cancer: why the search goes on; in Cisplatin. In Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 3-m27, Wiley-VCH, Basel
|
21 |
Sause, W. T., Scott, C., and Taylor, S. (1995) Radiation Therapy Oncology Group (RTOG 88-08) Eastern Cooperative Oncology Group (ECOG 4588): preliminary results of a phase III trial in regionally advanced unresectable nonsmall cell lung cancer with minimum three year follow-up (Abstr). Int. J. Rad. Oncol. Biol. Phys. 32, 109
|
22 |
Non-small lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 889-890
ScienceOn
|
23 |
Berclaz, G., Gerber, E., Beer, K., Aebi, S., Greiner, R., et al. (2002) Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-year survival after radiochemotherapy. Int. J. Oncol. 20, 1313-1318
|
24 |
Ahn, J. H., Kang, Y. K., Kim, T. W., Bahng, H., Chang, H. M., et al. (2002) Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother. Pharmacol. 50, 104-110
DOI
|
25 |
O'wyer, P. J., Johnson, S. W., and Hamilton, T. C. (1997) Pharmacology of cancer chemotherapy: cisplatin and its analogues; in Cancer: Principles and Practice of Oncology, De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds.), pp. 418-m432, Lippincott-Raven, Philadelphia
|
26 |
Rose, P. G. (2002) Chemoradiotherapy for cervical cancer. Eur. J. Cancer. 38, 270-278
DOI
ScienceOn
|
27 |
Durant, J. R. (1980) Cisplatin: a clinical overview; in Cisplatin, Current Status and New Developments, Prestayko, A. W., Crooke, S. T., and Carter, S. K. (eds.), pp. 317-321, Academic Press, New York, NY
|
28 |
Coughlin, C. T. and Richmond, R. C. (1989) Biological and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Sem. Oncol. 16, 31-43
|
29 |
Eastman, A. (1999) The mechanism of action of cisplatin: from adducts to apoptosis; in Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 111-134, Wiley-VCH, Basel
|
30 |
Muggia, F. M. and Norris, K. J. (1989) Future of cancer chemotherapy with cisplatin. Semin. Oncol. 16, 123
|
31 |
Soresi, E., Clerici, M., and Grilli, R. (1988) A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiamine (platinum III) in the treatment of locally advanced non-small cell lung cancer. Semin. Oncol. 15, 20-m25
|
32 |
Wong, L. C., Choo, Y. C., Choy, D., Sham, J. S., and Ma, H. K. (1989) Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol. Oncol. 35, 159-163
DOI
ScienceOn
|
33 |
Kim, D. K., Ahn, J. S., Ryu, G., Kim, K. H., Park, C. W., et al. (1994b) General pharmacology of cis-malonato(4R,5R)-4,5-bi(aminomet- hyl)-1,3-dioxolane-platinum(II) (SKI 2053R). Arzneim. Forsch. 44, 1080-1088
|
34 |
Kim, D. K., Kim, H. T., Cho, Y. B., Tai, J. H., Ahn, J. S., et al. (1995b) Antitumor activity of cis-malonato(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother. Pharmacol. 44, 441-445
|
35 |
Kim, S. J., Kim, J. E., and Moon, I. S. (2004) Paraquat induces apoptosis of cultured rat cortical cells. Mol. Cells 17, 102-m107
|
36 |
Merlano, M., Vitale, V., Rosso, R., Benasso, M., Corvo, R., et al. (1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115-m1121
ScienceOn
|
37 |
Tannock, I. F. (1989) Combined modality treatment with radiotherapy and chemotherapy. Radioth. Oncol. 16, 83-101
DOI
ScienceOn
|
38 |
Merlano, M., Corvo, R., Margarino, G., Benasso, M., Rosso, R., et al. (1991) Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67, 915-921
DOI
ScienceOn
|
39 |
Carter, S. K. (1984) Cisplatin-past, present and future; in Platinum Coordination Complexes in Cancer Chemotherapy, Hacker, M. P., Douple, E. B., and Krakoff, I. H. (eds.), pp. 359-376, Martinus Nijhoff Publishing, Boston
|
40 |
Kalendo, G. S. (2001) Different levels of radiation protection in tumor cell populations. Radiats. Biol. Radioecol. 41, 519-527
|
41 |
Loeher, P. J. and Einhorn, L. H. (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704
ScienceOn
|
42 |
Joiner, M. C., Marples, B., Lambin, P., Short, S. C., and Turesson, I. (2001) Low-dose hypersensitivity : current status and possible mechanisms. Int. J. Rad. Oncol. Biol. Phys. 49, 379-389
DOI
ScienceOn
|
43 |
Steel, G. G. and Peckham, M. J. (1979) Exploitable mechanism in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85-m91
|